Progress and Promise in the Identification and Management of Interstitial Lung Disease

Progress and Promise in the Identification and Management of Interstitial Lung Disease is organized by Paradigm Medical Communications, LLC and will be held from Jul 31, 2018 - Jul 31, 2019.

Target Audience
This activity has been designed to address the educational needs of pulmonologists, radiologists, and pathologists. The activity may also benefit primary care physicians, PAs, nurse practitioners, nurses, pharmacists, fellows, residents, and other allied healthcare providers who care for patients with interstitial lung disease.

Accreditation:
Physician Credit Designation Statement
Paradigm Medical Communications, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit.

PA Continuing Education
PAs may claim a maximum of 0.5 Category 1 credits for completing this activity.
 
Statement of Need
Interstitial lung diseases (ILDs) are progressive, severely debilitating, and often associated with high mortality. Detecting an ILD-and then differentiating it from the staggering array of diseases that fall under this umbrella-is further challenged by nonspecific, overlapping symptoms, which necessitate rigorous multidisciplinary evaluation to accurately assess patients. Early identification is more worthwhile than ever, given the availability of unprecedented treatment options that can slow the decline of lung function in patients with idiopathic pulmonary fibrosis (IPF). To ensure optimal outcomes, clinicians must become better acquainted with the in-depth, collaborative process necessary to clinch the detection and differentiation of ILDs; novel and emerging options to treat them; and ILD experts and centers that can support such a management scheme.
 
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
• Recognize signs and symptoms of interstitial lung disease and the importance of early referral of patients to interstitial lung disease specialists.
• Describe recommended diagnostic tests and methods of assessment for interstitial lung disease.
• Apply updated efficacy and safety data, recent guidelines, and individual patient characteristics, such as comorbidities, when making treatment decisions for patients with idiopathic pulmonary fibrosis.
• Outline effective communication strategies to engage patients in discussions about the course and management of interstitial lung disease.

Additional details will be posted as soon as they are available.